• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The frequency of prescription of P-glycoprotein-affecting drugs in atrial fibrillation.

作者信息

Jungbauer L, Dobias C, Stöllberger C, Weidinger F

出版信息

J Thromb Haemost. 2010 Sep;8(9):2069-70. doi: 10.1111/j.1538-7836.2010.03943.x.

DOI:10.1111/j.1538-7836.2010.03943.x
PMID:20553377
Abstract
摘要

相似文献

1
The frequency of prescription of P-glycoprotein-affecting drugs in atrial fibrillation.心房颤动中P-糖蛋白影响药物的处方频率。
J Thromb Haemost. 2010 Sep;8(9):2069-70. doi: 10.1111/j.1538-7836.2010.03943.x.
2
Therapeutic behavior of primary care physicians in patients with atrial fibrillation taking vitamin K antagonists not adequately controlled.
Eur J Intern Med. 2016 May;30:e17-e18. doi: 10.1016/j.ejim.2016.01.016. Epub 2016 Jan 28.
3
Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort.非维生素K拮抗剂口服抗凝药时代之前心房颤动患者的抗栓治疗：心房颤动患者长期口服抗栓治疗全球注册研究（GLORIA-AF）第一阶段队列研究
Europace. 2016 Sep;18(9):1308-18. doi: 10.1093/europace/euw073. Epub 2016 Jun 21.
4
Pharmacodynamic profile and drug interactions with non-vitamin K antagonist oral anticoagulants: implications for patients with atrial fibrillation.非维生素K拮抗剂口服抗凝药的药效学特征及药物相互作用：对心房颤动患者的影响
Expert Opin Drug Metab Toxicol. 2015 Jun;11(6):937-48. doi: 10.1517/17425255.2015.1027683. Epub 2015 Mar 22.
5
Future directions of stroke prevention in atrial fibrillation: the potential impact of novel anticoagulants and stroke risk stratification.未来房颤卒中预防的方向：新型抗凝药物和卒中风险分层的潜在影响。
J Thromb Haemost. 2011 Mar;9(3):441-9. doi: 10.1111/j.1538-7836.2010.04179.x.
6
Starting anticoagulation with vitamin k antagonists alone or with concomitant low-molecular weight heparin for non-valvular atrial fibrillation.
Eur J Intern Med. 2019 Jan;59:e14-e15. doi: 10.1016/j.ejim.2018.09.016. Epub 2018 Sep 28.
7
Shifting from vitamin K antagonists to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: predictors, patterns and temporal trends.在心房颤动患者中从维生素 K 拮抗剂转换为非维生素 K 拮抗剂口服抗凝剂：预测因素、模式和时间趋势。
BMC Cardiovasc Disord. 2021 Oct 13;21(1):493. doi: 10.1186/s12872-021-02295-w.
8
Dynamics of vitamin K antagonist and new oral anticoagulants use in atrial fibrillation: a Danish drug utilization study.维生素 K 拮抗剂和新型口服抗凝剂在心房颤动中的应用动态：一项丹麦药物利用研究。
J Thromb Haemost. 2014 Sep;12(9):1413-8. doi: 10.1111/jth.12662. Epub 2014 Aug 11.
9
Influence of age on the prescription of vitamin K antagonists in outpatients with permanent atrial fibrillation in France.
Pharmacoepidemiol Drug Saf. 2007 Jan;16(1):32-8. doi: 10.1002/pds.1329.
10
Long-term vitamin K antagonists treatment patterns of Non-Valvular Atrial Fibrillation (NVAF): a population-based cohort study.非瓣膜性心房颤动（NVAF）的长期维生素K拮抗剂治疗模式：一项基于人群的队列研究。
BMC Cardiovasc Disord. 2016 May 10;16:84. doi: 10.1186/s12872-016-0269-4.

引用本文的文献

1
Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study.因出血事件入院患者的利伐沙班血浆水平：一项前瞻性研究的见解
Thromb J. 2018 Nov 12;16:28. doi: 10.1186/s12959-018-0183-3. eCollection 2018.
2
Effect of ABCB1 genetic polymorphisms on the transport of rivaroxaban in HEK293 recombinant cell lines.ABCB1 基因多态性对瑞伐沙班在 HEK293 重组细胞系中转运的影响。
Sci Rep. 2018 Jul 12;8(1):10514. doi: 10.1038/s41598-018-28622-4.
3
In Vitro Comparison of the Role of P-Glycoprotein and Breast Cancer Resistance Protein on Direct Oral Anticoagulants Disposition.
P-糖蛋白和乳腺癌耐药蛋白在直接口服抗凝剂处置中作用的体外比较
Eur J Drug Metab Pharmacokinet. 2018 Apr;43(2):183-191. doi: 10.1007/s13318-017-0434-x.
4
Perioperative management of patients on direct oral anticoagulants.接受直接口服抗凝剂治疗患者的围手术期管理。
Thromb J. 2017 May 15;15:14. doi: 10.1186/s12959-017-0137-1. eCollection 2017.
5
Rivaroxaban-Induced Hemorrhage Associated with Genetic Defect.利伐沙班所致出血与基因缺陷相关
Front Pharmacol. 2016 Dec 19;7:494. doi: 10.3389/fphar.2016.00494. eCollection 2016.
6
Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants.非维生素K拮抗剂口服抗凝剂围手术期及急诊管理的进展
Crit Care. 2015 Apr 29;19(1):203. doi: 10.1186/s13054-015-0930-9.
7
Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban.P-糖蛋白在达比加群、利伐沙班和阿哌沙班预防卒中中的相关性。
Herz. 2015 Apr;40 Suppl 2:140-5. doi: 10.1007/s00059-014-4188-9. Epub 2015 Jan 25.
8
Concerns regarding the use of dabigatran for stroke prevention in atrial fibrillation.对达比加群酯用于房颤卒中预防的担忧。
Pharmaceuticals (Basel). 2012 Feb 3;5(2):155-68. doi: 10.3390/ph5020155.
9
Optimizing the use of anticoagulants (heparins and oral anticoagulants) in the elderly.优化老年人抗凝剂（肝素和口服抗凝剂）的使用。
Drugs Aging. 2013 Sep;30(9):687-99. doi: 10.1007/s40266-013-0101-0.
10
Dabigatran and kidney disease: a bad combination.达比加群酯与肾病：不良组合。
Clin J Am Soc Nephrol. 2013 Sep;8(9):1591-7. doi: 10.2215/CJN.01260213. Epub 2013 Jul 18.